Scientists have been unsuccessfully trying to create an HIV vaccine
since 1987. However, researchers at Scripps Research Institute may be close
to it, as their HIV vaccine candidate induced antibodies against the
disease in 97% of participants in Phase 1 clinical trial.The vaccine also had a favorable safety profile. Still, it is too early to
tell if the shot could protect against the human immunodeficiency virus,
affecting 1.2 million people in the U.S.
since 1987. However, researchers at Scripps Research Institute may be close
to it, as their HIV vaccine candidate induced antibodies against the
disease in 97% of participants in Phase 1 clinical trial.The vaccine also had a favorable safety profile. Still, it is too early to
tell if the shot could protect against the human immunodeficiency virus,
affecting 1.2 million people in the U.S.
The researchers in the study use a strategy known as “germline targeting,”
where the production of desired broadly neutralizing antibodies is launched
by stimulating the right antibody-producing cells.
